Gulnara Yuldasheva | Drug Synergy | Women Researcher Award

Published on by Global Diseases Research

Women Researcher Award

Research Profile
Affiliation Scientific Center for Anti-Infective Drug
Country Kazakhstan
Scopus ID 21735405800
Documents 7
Citations 35
h-index 5
Subject Area Drug synergy
Event Global Diseases Research Awards
ORCID 0000-0003-2881-0307

Gulnara Yuldasheva is associated with the Scientific Center for Anti-Infective Drug in Kazakhstan and has contributed to the advancement of research in drug synergy and anti-infective therapeutic studies. Her scholarly work reflects a focused engagement in antimicrobial research, pharmaceutical sciences, and collaborative approaches to disease-related investigations. The academic profile demonstrates measurable research visibility through indexed publications, citations, and international scholarly recognition.[1]

Abstract

The Women Researcher Award recognizes academic and scientific contributions that demonstrate relevance, scholarly consistency, and engagement with emerging challenges in biomedical and pharmaceutical sciences. Gulnara Yuldasheva has contributed to the field of anti-infective drug research with particular attention to drug synergy, antimicrobial investigations, and interdisciplinary pharmaceutical approaches. Her research activities are represented through indexed scientific publications and citation-based academic visibility, indicating active participation in internationally recognized scientific communication.[1][2]

Keywords

  • Drug synergy
  • Anti-infective research
  • Pharmaceutical sciences
  • Biomedical research
  • Women in science
  • Global Diseases Research Awards

Introduction

Research in anti-infective therapeutics continues to play a significant role in addressing global public health challenges related to infectious diseases and antimicrobial resistance. Scientific investigations involving drug synergy provide insights into the combined effects of therapeutic compounds and contribute to the optimization of treatment strategies. Researchers engaged in this domain support evidence-based approaches that may improve clinical outcomes and pharmaceutical innovation.[2]

Gulnara Yuldasheva’s academic profile reflects participation in research initiatives connected with anti-infective drug development and interdisciplinary pharmaceutical studies. Her scholarly contributions demonstrate engagement with research dissemination through indexed databases and internationally accessible scientific literature. Such contributions align with the broader objectives of scientific collaboration and innovation in health-related research environments.[1]

Research Profile

The research profile of Gulnara Yuldasheva is associated with studies in anti-infective pharmacology and drug synergy analysis. Her work has contributed to the understanding of therapeutic interactions and scientific approaches relevant to infectious disease management. Indexed publications and citation metrics indicate continuing scholarly engagement within biomedical and pharmaceutical research communities.[1]

  • Affiliated with the Scientific Center for Anti-Infective Drug.
  • Research specialization includes drug synergy and anti-infective therapeutics.
  • Indexed scientific publications available through Scopus.
  • Recognized through measurable citation impact and academic visibility.
  • Engaged in interdisciplinary biomedical and pharmaceutical studies.

Research Contributions

Research contributions associated with Gulnara Yuldasheva include scientific investigations into anti-infective compounds, synergistic drug interactions, and pharmaceutical research methodologies. Such studies support broader scientific understanding related to therapeutic combinations and their relevance in infectious disease management.[2]

Drug synergy research is important for evaluating combined therapeutic effectiveness, minimizing resistance development, and identifying optimized treatment approaches. Through scholarly publication activity, Yuldasheva has contributed to ongoing scientific discussions in this specialized area of pharmaceutical sciences and biomedical investigation.[3]

Publications

The publication record associated with Gulnara Yuldasheva reflects contributions to scientific literature indexed within internationally recognized academic databases. Her scholarly output demonstrates participation in peer-reviewed communication relevant to anti-infective pharmacology and biomedical research.[1]

  1. Research studies addressing anti-infective therapeutic strategies and drug interaction analysis.
  2. Molecular Modeling of the Anti-HIV Activity Mechanism of Iodine-Containing Drugs Armenicum and FS-1Article link copied! [3]
  3. Iodine-Based Coordination Compounds: A Strategy Toward Antibiotic Potentiation [4]

Research Impact

Research impact may be evaluated through publication indexing, citation activity, and scholarly engagement across scientific platforms. The citation profile associated with Gulnara Yuldasheva demonstrates recognition within academic literature and indicates that her work has contributed to discussions related to pharmaceutical and anti-infective sciences.[1]

The documented h-index and citation metrics reflect measurable academic visibility within the scientific community. Such indicators support the significance of continued research participation and contribution to interdisciplinary biomedical knowledge dissemination.[1]

Award Suitability

The Women Researcher Award within the Global Diseases Research Awards framework recognizes scientific contributions that support research excellence, innovation, and scholarly engagement in health sciences. Gulnara Yuldasheva’s profile demonstrates alignment with these objectives through her involvement in anti-infective drug research, indexed scientific output, and measurable citation impact.[5]

Her academic activities indicate sustained participation in biomedical and pharmaceutical investigations relevant to global health and therapeutic innovation. The combination of publication visibility, research specialization, and international indexing supports the suitability of recognition within a research-oriented academic award context.[1]

Conclusion

Gulnara Yuldasheva has contributed to scientific research associated with anti-infective therapeutics and drug synergy studies through indexed publications and interdisciplinary academic engagement. Her scholarly profile reflects measurable research visibility and participation in pharmaceutical science communication. The academic contributions and citation-based impact presented within this profile demonstrate relevance to contemporary biomedical research and support recognition within the Women Researcher Award category of the Global Diseases Research Awards.[1][5]

References

  1. Elsevier. (n.d.). Scopus author details: Gulnara Yuldasheva, Author ID 21735405800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=21735405800
  2. World Health Organization. (2023). Antimicrobial resistance and anti-infective therapeutic research.
    https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
  3. Yuldasheva, G. A., Argirova, R., & Ilin, A. I. (2023). Molecular modeling of the anti-HIV activity mechanism of iodine-containing drugs Armenicum and FS-1. ACS Omega, 8(9), 8617–8624
    https://doi.org/10.1021/acsomega.2c07720

  4. Shepilov, D., Askarova, D., Seisembekova, A., Turganbay, S., Jumagaziyeva, A., Bukeyeva, T., Yuldasheva, G., Temir, N., Ivanova, L. N., Zubenko, N., & Kenesheva, S. (2026). Iodine-based coordination compounds: A strategy toward antibiotic potentiation. International Journal of Molecular Sciences, 27(10), 4292.
    https://doi.org/10.3390/ijms27104292

  5. Global Diseases Research Awards. (n.d.). Women Researcher Award recognition and event information.
    https://globaldiseases.org/

Prof. Dr. Zeynep Koloren | Molecular Pharmacology | Women Researcher Award

Published on by Global Diseases Research

Prof. Dr. Zeynep Koloren | Molecular Pharmacology | Women Researcher Award

Ordu University | Turkey

Prof. Dr. Zeynep Kolören is a distinguished academic affiliated with Ordu Üniversitesi, specializing in parasitology, molecular biology, and antimicrobial research with a strong focus on protozoan pathogens such as Acanthamoeba castellanii. With a robust research portfolio comprising 41 peer-reviewed publications and 352 citations, and an h-index of 12, she has demonstrated consistent scholarly impact and scientific productivity. Her work integrates natural product research, gene expression analysis, and nanotechnology-based therapeutic approaches, contributing to advancements in infectious disease control. Prof. Kolören has actively collaborated with a network of 47 co-authors, reflecting her engagement in interdisciplinary and international research efforts. Her studies on plant-derived compounds and novel antimicrobial agents highlight a commitment to developing sustainable and effective solutions for global health challenges, reinforcing her contribution to both scientific knowledge and societal well-being.

Citation Metrics (Scopus)
352
290
150
50
0

Citations

352

Documents

41

h-index

12

Citations

Documents

h-index

View Scopus Profile
   View Google Scholar Profile

Top 5 Featured Publications

 

Xiaolin Hou | Veterinary Pharmacology | Best Researcher Award

Published on by Global Diseases Research

Mr. Xiaolin Hou | Veterinary Pharmacology | Best Researcher Award 

Professor | Beijing University of Agriculture | China

Dr. Xiaolin Hou is a distinguished researcher affiliated with Beijing University of Agriculture, specializing in veterinary virology, immunology, and nanobiotechnology applications in animal health. With a prolific portfolio of 58 publications and over 1,200 citations, Dr. Hou has significantly contributed to the understanding of viral pathogenesis and host immune modulation, particularly in chronic hepatitis B and porcine reproductive and respiratory syndrome virus. His research emphasizes innovative approaches to disease prevention and therapeutic interventions, including nanoparticle-mediated drug delivery, quantum dot polymer inhibitors, and advanced immunoassay techniques for mycotoxin detection. Collaborating extensively with a global network of 174 co-authors, Dr. Hou integrates multidisciplinary expertise across molecular biology, food safety, and pharmaceutical sciences to develop practical solutions for veterinary and public health challenges. His work demonstrates a consistent focus on enhancing immune responses, suppressing pathogenic mechanisms, and improving disease diagnostics, reflecting both academic rigor and societal impact. Notably, Dr. Hou’s research bridges fundamental science with applied technologies, fostering advancements in animal therapeutics, vaccine development, and food safety monitoring. Recognized for both methodological innovation and translational relevance, his contributions continue to shape contemporary approaches in veterinary pharmacology and virology research on an international scale.

Profiles: Scopus | ORCID

Featured Publications

1. Han, C., Xu, W., Wang, J., Hou, X., Zhou, S., Song, Q., Liu, X., & Li, H. (2023). Porcine circovirus 2 increases the frequency of transforming growth factor-β via the C35, S36 and V39 amino acids of the ORF4. Viruses, 15(7), 1602.

2. Liu, X., Wang, Y., Han, C., Li, Q., Hou, X., Song, Q., Zhou, S., & Li, H. (2022). TGF-β from the porcine intestinal cell line IPEC-J2 induced by porcine circovirus 2 increases the frequency of Treg cells via the activation of ERK (in CD4⁺ T cells) and NF-κB (in IPEC-J2). Viruses, 14(11), 2466

3. Hou, X. (2022). A berberine hydrochloride–carboxymethyl chitosan hydrogel protects against Staphylococcus aureus infection in a rat mastitis model. Carbohydrate Polymers, 282, 118910.

4. Hou, X. (2022). Lithium chloride inhibits infectious bronchitis virus-induced apoptosis and inflammation. Microbial Pathogenesis, 162, 105352.

5. Hou, X. (2021). Antibacterial activity and membrane-targeting mechanism of aloe-emodin against Staphylococcus epidermidis. Frontiers in Microbiology, 12, 621866.

Dr. Xiaolin Hou’s research advances animal and human health through innovative applications of nanotechnology, immunoassays, and antiviral strategies. By elucidating molecular mechanisms in viral infections and immune modulation, their work contributes to disease prevention, therapeutic development, and global food safety, bridging fundamental science with practical solutions for public health and veterinary medicine.